All In Biotech

Drug Trial Radar · NCT07371338

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

Dose-Escalation, Single-Center, Open-label Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Adeno-associated Virus(AAV) Gene Therapy Product IPS101A in Parkinson's Disease Patients With Hoehn-Yahr Stage 4-5, Diagnosed in More Than 10 Years and Uncontrolled by All Available Monotherapy or Combination Therapy

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

Jun 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Innopeutics CorporationIndustry
Sponsor type
Industry
First posted
Jan 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn \& Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.

Conditions

  • Parkinson Disease
  • Parkinson's Disease

Interventions

  • IPS101ADrug

    The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Evaluation: dose-limiting toxicity (DLT)Time frame: Baseline to Week 8
  2. Safety Evaluation: Severity and frequency of reported adverse eventsTime frame: Baseline to Week 52
  3. Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnelTime frame: Baseline to Week 52
  4. Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnelTime frame: Baseline to Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.